[Current Status and Prospects of RI Internal Therapy for Prostate Cancer].
1/5 보강
Most castration-sensitive prostate cancers(CSPC)with metastases progress to castration-resistant prostate cancer(CRPC)within a few years.
APA
Uemura H, Ito Y, Kawahara T (2025). [Current Status and Prospects of RI Internal Therapy for Prostate Cancer].. Gan to kagaku ryoho. Cancer & chemotherapy, 52(7), 505-511.
MLA
Uemura H, et al.. "[Current Status and Prospects of RI Internal Therapy for Prostate Cancer].." Gan to kagaku ryoho. Cancer & chemotherapy, vol. 52, no. 7, 2025, pp. 505-511.
PMID
40840895 ↗
Abstract 한글 요약
Most castration-sensitive prostate cancers(CSPC)with metastases progress to castration-resistant prostate cancer(CRPC)within a few years. In recent years, upfront treatment with second-generation antiandrogens, novel hormonal agents (ARSIs)and taxanes, administered at the mCSPC stage, has been developed and the evidence of delaying the time to reach CRPC has been reported. However, once the disease progresses to CRPC, there are few treatment options and no effective treatment sequence has been established. Ra223 as radiotherapy for bone metastases in mCRPC treatment has shown prolonged survival benefits, similar to ARSI and taxane-based anticancer drugs, and is widely used in Japan. Recently, prostate-specific membrane antigen(PSMA)-lutetium therapy, in which PSMA is coupled to 177Lutetium and administered systemically, has been developed in Western countries for mCRPC expressing PSMA and is an effective RI therapy that reduces bone and visceral metastases. It is expected to be covered by health insurance in Japan in the near future and is expected to be a promising treatment for mCRPC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.